You are here: Industry Insights > fulvestrant

News List

NICE recommends Eli Lilly’s breast cancer drug Verzenios pharmatimes
August 13, 2021
Draft NICE guidance has recommended Eli Lilly’s twice-daily pill Verzenios (abemaciclib) as an option for adults with a type of breast cancer called hormone receptor-positive, HER2-negative breast cancer which has spread to other parts of the body.
NICE rejects Lilly’s Verzenios for advanced breast cancer pharmatimes
February 19, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has not recommended Eli Lilly’s Verzenios (abemaciclib) with fulvestrant for the treatment of advanced breast cancer patients.
Pii to Manufacture FDA-Approved Hormone Therapy Injection Drug Product contractpharma
September 24, 2019
Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) headquartered in Hunt Valley, MD, will manufacture commercial supply of Fulvestrant Injection 250mg/5ml drug product ...
Novartis’ Piqray Approved as First PI3K Inhibitor for Breast Cancer drugs
June 03, 2019
Novartis’ Piqray Approved as First PI3K Inhibitor for Breast Cancer.